127 related articles for article (PubMed ID: 32078308)
1. Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types.
Wang G; Zhao Y; Liu Y; Sun D; Zhen Y; Liu J; Fu L; Zhang L; Ouyang L
J Med Chem; 2020 Apr; 63(8):3976-3995. PubMed ID: 32078308
[TBL] [Abstract][Full Text] [Related]
2. The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.
Wang X; Pesakhov S; Harrison JS; Kafka M; Danilenko M; Studzinski GP
Exp Cell Res; 2015 Jan; 330(1):199-211. PubMed ID: 25447310
[TBL] [Abstract][Full Text] [Related]
3. DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.
Arkell RS; Dickinson RJ; Squires M; Hayat S; Keyse SM; Cook SJ
Cell Signal; 2008 May; 20(5):836-43. PubMed ID: 18280112
[TBL] [Abstract][Full Text] [Related]
4. ERK5 induces ankrd1 for catecholamine biosynthesis and homeostasis in adrenal medullary cells.
Obara Y; Nagasawa R; Nemoto W; Pellegrino MJ; Takahashi M; Habecker BA; Stork PJS; Ichiyanagi O; Ito H; Tomita Y; Ishii K; Nakahata N
Cell Signal; 2016 Mar; 28(3):177-189. PubMed ID: 26739108
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM; Miller DC; Molyneux L; Arasta M; Bawn RH; Blackburn TJ; Cook SJ; Edwards N; Endicott JA; Golding BT; Griffin RJ; Hammonds T; Hardcastle IR; Harnor SJ; Heptinstall AB; Lochhead PA; Martin MP; Martin NC; Newell DR; Owen PJ; Pang LC; Reuillon T; Rigoreau LJM; Thomas HD; Tucker JA; Wang LZ; Wong AC; Noble MEM; Wedge SR; Cano C
Eur J Med Chem; 2019 Sep; 178():530-543. PubMed ID: 31212132
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract][Full Text] [Related]
7. Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity.
Kedika SR; Shukla SP; Udugamasooriya DG
Bioorg Med Chem Lett; 2020 Dec; 30(23):127552. PubMed ID: 32946922
[TBL] [Abstract][Full Text] [Related]
8. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
9. The ERK5 and ERK1/2 signaling pathways play opposing regulatory roles during chondrogenesis of adult human bone marrow-derived multipotent progenitor cells.
Bobick BE; Matsche AI; Chen FH; Tuan RS
J Cell Physiol; 2010 Jul; 224(1):178-86. PubMed ID: 20232315
[TBL] [Abstract][Full Text] [Related]
10. ERK1/2 and ERK5 have distinct roles in the regulation of brain-derived neurotrophic factor expression.
Su C; Underwood W; Rybalchenko N; Singh M
J Neurosci Res; 2011 Oct; 89(10):1542-50. PubMed ID: 21647938
[TBL] [Abstract][Full Text] [Related]
11. Basic fibroblast growth factor promotes glial cell-derived neurotrophic factor gene expression mediated by activation of ERK5 in rat C6 glioma cells.
Obara Y; Nemoto W; Kohno S; Murata T; Kaneda N; Nakahata N
Cell Signal; 2011 Apr; 23(4):666-72. PubMed ID: 21130871
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
13. Retrograde neurotrophic signaling in rat retinal ganglion cells is transmitted via the ERK5 but not the ERK1/2 pathway.
van Oterendorp C; Sgouris S; Schallner N; Biermann J; Lagrèze WA
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):658-65. PubMed ID: 24398098
[TBL] [Abstract][Full Text] [Related]
14. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling.
Mansour MA; Hyodo T; Ito S; Kurita K; Kokuryo T; Uehara K; Nagino M; Takahashi M; Hamaguchi M; Senga T
FEBS J; 2015 Apr; 282(8):1394-405. PubMed ID: 25662172
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
[TBL] [Abstract][Full Text] [Related]
16. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress.
Cavanaugh JE; Jaumotte JD; Lakoski JM; Zigmond MJ
J Neurosci Res; 2006 Nov; 84(6):1367-75. PubMed ID: 16941494
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Nguyen D; Lemos C; Wortmann L; Eis K; Holton SJ; Boemer U; Moosmayer D; Eberspaecher U; Weiske J; Lechner C; Prechtl S; Suelzle D; Siegel F; Prinz F; Lesche R; Nicke B; Nowak-Reppel K; Himmel H; Mumberg D; von Nussbaum F; Nising CF; Bauser M; Haegebarth A
J Med Chem; 2019 Jan; 62(2):928-940. PubMed ID: 30563338
[TBL] [Abstract][Full Text] [Related]
19. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
20. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Vaseva AV; Blake DR; Gilbert TSK; Ng S; Hostetter G; Azam SH; Ozkan-Dagliyan I; Gautam P; Bryant KL; Pearce KH; Herring LE; Han H; Graves LM; Witkiewicz AK; Knudsen ES; Pecot CV; Rashid N; Houghton PJ; Wennerberg K; Cox AD; Der CJ
Cancer Cell; 2018 Nov; 34(5):807-822.e7. PubMed ID: 30423298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
